|
Microfluidic and Organotypic Tumor Slice Culture Drug Testing Platform for Individualized Cancer Therapy
Application
A drug combination screening/testing platform for individualized cancer therapy.
Key Benefits
Rapid screening of effective drug combination.
Integrated tumor microenvironment.
Identifying personalized therapy for individual cancer patient.
Market Summary
Traditional two-dimensional (2D) in vitro culture models for drug development...
Published: 7/6/2022
Contributor(s): Tobey John MacDonald, Anna Kenney, Abhinav Dey, YongTae (Tony) Kim
|
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type...
Published: 7/6/2022
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
|
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform
Application
High Throughput Screening for identifying effective immuno-modulators.
Key Benefits
HT screening platform replicating complex immune medicated response to facilitate discovery of small molecule immunomodulatory agents.
Simplicity and dual readouts of the design enable the screening of large chemical libraries to identify compounds...
Published: 5/17/2022
Contributor(s): Xiulei Mo, Haian Fu
|
|
Multifunctional Drug and Immune Modulator Delivery Nanoparticles for the Treatment of Cancer Patients with Comorbid Atherosclerosis
Application
A multifunctional immuno-therapy nanoparticle (PD1Y-HANP/Avasimbe) that has ability of targeting and inhibiting immune checkpoint PDL-1 while producing therapeutic effects on tumors and atherosclerosis.
Key Benefits
Multifunctional immunotherapy for cancer patients with atherosclerosis.
Shown to inhibit tumor growth and prevention...
Published: 5/13/2022
Contributor(s): Lily Yang, Lei Zhu
|
|
Using a Theranostic for Imaging and Treating Glioma
Application
A small molecule imaging agent for imaging gliomas.
Key Benefits
Potentially increased specificity and sensitivity compared to existing imaging agents.
Market Summary
Glioma is the most common form of central nervous system neoplasm originating from the brain's glial cells. These cancers are diffusely infiltrative tumors...
Published: 5/13/2022
Contributor(s): Mark Goodman, Lanny Liebeskind, Hui Mao, Gouthami Pashikanti
|
|
Mitigation of Negative Effects of Melphalan on Cardiomyocytes with N-acetyl-L-cysteine (NAC) Treatment
Application
NAC (N-acetyl-L-cystine) as an antioxidant to reduce chemotherapy induced oxidative stress and cardiotoxicity.
Key Benefits
Mitigates cardiotoxic side effects of alkylating agent, melphalan in human cardiomyocytes.
Market Summary
Melphalan is a chemotherapeutic commonly used to treat various cancers including multiple myeloma,...
Published: 5/13/2022
Contributor(s): Chunhui Xu, Anant Mandawat, Rui Liu
|
|
Small Molecule Compound to Treat Neurological Diseases
Application
NMDAR agents for the treatment of various neurological diseases.
Key Benefits
Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs.
The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility.
The initial studies have determined...
Published: 5/13/2022
Contributor(s): Dennis Liotta, Stephen Traynelis, Hongjie Yuan, Matthew Epplin, Samantha Summer, David Menaldino, Leon Jacobs, Adam McCallum
|
|
SARS-CoV-2 Subgenomic Replicon (SARS2-Rn)
Application
A series of SARS-CoV-2 sub-genomic replicons as artificial bacterial chromosomes for the screening of SARS-CoV-2 in studies such as drug discovery and inhibitors assay.
Key Benefits
Can be used at a lower biosafety level than non-artificial copies of SARS-CoV-2.
Can be used for high throughput screening and characterization...
Published: 4/19/2022
Contributor(s): Stefan Sarafianos, Shuiyun Lan
|
|
Serological Test for SARS-CoV-2
Application
Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.
Key Benefits
Highly specific and sensitive.
Fewer false positives than commercially available tests.
Market Summary
SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing...
Published: 1/24/2022
Contributor(s): Rafi Ahmed, Mehul Suthar, John Roback, Jens Wrammert, Robert Kauffman
|
|
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application
Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells.
Key Benefits
First in class, targeted immunotherapy for patients presented with KRASG12V mutation.
Attenuates immune suppression associated with KRASG12V-positive cancers.
Market Summary
The KRASG12V mutation, representing 85% of all cancer mutations,...
Published: 1/7/2022
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|